These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 36442453)
1. Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor. Wienen F; Nilson R; Allmendinger E; Graumann D; Fiedler E; Bosse-Doenecke E; Kochanek S; Krutzke L Biomater Adv; 2023 Jan; 144():213208. PubMed ID: 36442453 [TBL] [Abstract][Full Text] [Related]
2. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Morrison J; Briggs SS; Green NK; Thoma C; Fisher KD; Kehoe S; Seymour LW Hum Gene Ther; 2009 Mar; 20(3):239-51. PubMed ID: 19257852 [TBL] [Abstract][Full Text] [Related]
3. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Blackwell JL; Miller CR; Douglas JT; Li H; Reynolds PN; Carroll WR; Peters GE; Strong TV; Curiel DT Arch Otolaryngol Head Neck Surg; 1999 Aug; 125(8):856-63. PubMed ID: 10448731 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic effect of Midkine promoter-based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891. Uehara N; Otsuki N; Kubo M; Kitamoto J; Kojima Y; Teshima M; Shinomiya H; Shirakawa T; Nibu KI Cancer Rep (Hoboken); 2020 Jun; 3(3):e1231. PubMed ID: 32671980 [TBL] [Abstract][Full Text] [Related]
5. Smart Accumulating Dual-Targeting Lipid Envelopes Equipping Oncolytic Adenovirus for Enhancing Cancer Gene Therapeutic Efficacy. Zhao Y; Le TMD; Hong J; Jiao A; Yoon AR; Yun CO ACS Nano; 2024 Oct; 18(41):27869-27890. PubMed ID: 39356167 [TBL] [Abstract][Full Text] [Related]
6. Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies. Uusi-Kerttula H; Legut M; Davies J; Jones R; Hudson E; Hanna L; Stanton RJ; Chester JD; Parker AL Hum Gene Ther; 2015 May; 26(5):320-9. PubMed ID: 25919378 [TBL] [Abstract][Full Text] [Related]
7. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. van Beusechem VW; Grill J; Mastenbroek DC; Wickham TJ; Roelvink PW; Haisma HJ; Lamfers ML; Dirven CM; Pinedo HM; Gerritsen WR J Virol; 2002 Mar; 76(6):2753-62. PubMed ID: 11861842 [TBL] [Abstract][Full Text] [Related]
8. Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. Harvey TJ; Burdon D; Steele L; Ingram N; Hall GD; Selby PJ; Vile RG; Cooper PA; Shnyder SD; Chester JD Gene Ther; 2010 Aug; 17(8):1000-10. PubMed ID: 20410926 [TBL] [Abstract][Full Text] [Related]
9. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer. Toivonen R; Suominen E; Grenman R; Savontaus M Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458 [TBL] [Abstract][Full Text] [Related]
10. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043 [TBL] [Abstract][Full Text] [Related]
11. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Smith T; Idamakanti N; Kylefjord H; Rollence M; King L; Kaloss M; Kaleko M; Stevenson SC Mol Ther; 2002 Jun; 5(6):770-9. PubMed ID: 12027562 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas. Nilson R; Krutzke L; Wienen F; Rojewski M; Zeplin PH; Funk W; Schrezenmeier H; Kochanek S; Kritzinger A Viruses; 2023 Jan; 15(1):. PubMed ID: 36680258 [TBL] [Abstract][Full Text] [Related]
14. Down-regulation of multiple cell survival proteins in head and neck cancer cells by an apoptogenic mutant of adenovirus type 5. Vijayalingam S; Subramanian T; Ryerse J; Varvares M; Chinnadurai G Virology; 2009 Sep; 392(1):62-72. PubMed ID: 19631957 [TBL] [Abstract][Full Text] [Related]
15. Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo. Lee S; Ahn HJ Acta Biomater; 2019 Jun; 91():258-269. PubMed ID: 31026519 [TBL] [Abstract][Full Text] [Related]
17. Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX. Stepanenko AA; Chekhonin VP Virus Res; 2018 Sep; 257():40-51. PubMed ID: 30125593 [TBL] [Abstract][Full Text] [Related]
18. Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus. Suominen E; Toivonen R; Grenman R; Savontaus M J Gene Med; 2006 Oct; 8(10):1223-31. PubMed ID: 16941521 [TBL] [Abstract][Full Text] [Related]
19. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer. Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292 [TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]